Back to companies

Mersana Therapeutics Inc: Premium Databases

Mersana Therapeutics Inc Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

A sample of Mersana Therapeutics Inc Insights data

Headline Published Journalists
Showing 3 of 5 results. Subscribe to unlock more.
Deserunt mollit sunt Lorem laborum do id aliqua dolore 14 Jun 2021 Lorem
Mersana’s XMT-1522 Her2+ breast cancer toxicity, efficacy results too early to validate platform but encouraging - experts 19 Jun 2018 Manasi Vaidya
Mersana’s Phase I ADC oncology study to enroll 120-140 patients in 2018, work with CRO Novella Clinical Research-CMO 06 Oct 2017 Manasi Vaidya
Mersana employs CRO Novella for Phase I ADC breast cancer therapy - CEO 30 Nov 2016 Alissa Fleck


Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.


Drug Insights:

  • Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
  • Material intelligence on competitors, including breaking news
  • Insight on companies’ business development needs and strategies

Outsourcing Insights:

Insight on companies’ CRO and business development needs, strategies and relationships


Remove risk and uncertainty

Gain a competitive edge

Secure actionable leads

Premium databases is part of our industry range of products

Subscribe to Company Analytics & gain 12-month access to premium industry data & analytics
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.


Access more premium companies when you subscribe to Explorer